Blood Proteins Patents (Class 435/69.6)
-
Patent number: 11965025Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.Type: GrantFiled: August 18, 2022Date of Patent: April 23, 2024Assignee: Marengo Therapeutics, Inc.Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
-
Patent number: 11958903Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.Type: GrantFiled: March 29, 2019Date of Patent: April 16, 2024Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Wang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
-
Patent number: 11958896Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.Type: GrantFiled: May 2, 2018Date of Patent: April 16, 2024Assignee: Prothena Biosciences LimitedInventors: Robin Barbour, Svetlana Alexander, Mark Renz, Shuning Gai, Tarlochan S. Nijjar, Philip James Dolan, III, Philip Payne
-
Patent number: 11945874Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Patent number: 11945839Abstract: The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.Type: GrantFiled: December 20, 2018Date of Patent: April 2, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Thomas Von Hirschheydt, Petra Rueger, Birgit Weydanz, Hubert Hertenberger
-
Patent number: 11939393Abstract: Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-? polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.Type: GrantFiled: February 22, 2022Date of Patent: March 26, 2024Assignee: ALX Oncology Inc.Inventors: Jaume Pons, Bang Janet Sim, Hong Wan, Tracy Chia-Chien Kuo
-
Patent number: 11919949Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.Type: GrantFiled: September 27, 2018Date of Patent: March 5, 2024Assignee: ELASMOGEN LTDInventors: Obinna Ubah, Caroline Barelle, Andrew Porter
-
Patent number: 11912741Abstract: The present disclosure relates to methods and systems for the continuous production of recombinant proteins. In particular embodiments, the disclosure relates to methods and systems using capture chromatography, post-capture chromatography, virus filtration, and ultrafiltration/diafiltration for the continuous production of recombinant proteins.Type: GrantFiled: April 1, 2020Date of Patent: February 27, 2024Assignee: GENZYME CORPORATIONInventors: Michael Coolbaugh, Tarl Vetter, Chad Varner, Kevin Brower
-
Patent number: 11897939Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: GrantFiled: October 9, 2020Date of Patent: February 13, 2024Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins UniversityInventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Patent number: 11891432Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.Type: GrantFiled: March 15, 2019Date of Patent: February 6, 2024Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology & ResearchInventors: Katja Fink, Cheng-I Wang, Lisa Fong Poh Ng, Laurent Renia, Zenjiro Sampei, Xing'er Christine Xoo
-
Patent number: 11891430Abstract: Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 ?m and 0.8 ?m pore size and a second filter of 0.45 ?m and 0.22 ?m pore size.Type: GrantFiled: October 22, 2019Date of Patent: February 6, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Roberto Falkenstein, Klaus Schwendner
-
Patent number: 11891448Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.Type: GrantFiled: November 1, 2021Date of Patent: February 6, 2024Assignee: President and Fellows of Harvard CollegeInventors: Jose A. Halperin, Michael Chorev
-
Patent number: 11891441Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.Type: GrantFiled: August 5, 2022Date of Patent: February 6, 2024Assignee: ELI LILLY AND COMPANYInventors: Shane Krummen Atwell, Yiqing Feng, Maya Rachel Karta, Donmienne Leung, Songqing Na, Diana Isabel Ruiz, David John Stokell, Laura Anne Pelletier
-
Patent number: 11866512Abstract: The present disclosure concerns antibodies and antibody fragments binding to citrullinated proteins (ACPA), and their use in prevention and treatment of autoimmune diseases, specifically rheumatoid arthritis (RA).Type: GrantFiled: November 22, 2018Date of Patent: January 9, 2024Assignee: Vacara ABInventors: Rikard Holmdahl, Theo Rispens, Bingze Xu, Changrong Ge
-
Patent number: 11866492Abstract: A modified antibody that binds specifically to folate receptor alpha (FOLR1) and blocks the activity of FOLR1 with an increased binding affinity, an antigen-binding fragment thereof, a composition containing the antibody or fragment, and their uses are disclosed. The modified antibody or antigen-binding fragment thereof may be used for the prevention or treatment of cancer proliferative disorder associated with an increased FOR1 expression, and may also be used for diagnosis of the disease. The proliferative disorder may be cancer.Type: GrantFiled: March 13, 2019Date of Patent: January 9, 2024Assignee: ALTEOGEN, INC.Inventors: Soon Jae Park, Hye-Shin Chung, Sunbae Lee
-
Patent number: 11859001Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.Type: GrantFiled: August 5, 2021Date of Patent: January 2, 2024Assignee: Synthekine, Inc.Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
-
Patent number: 11858997Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: October 13, 2020Date of Patent: January 2, 2024Assignee: Ablynx N.V.Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
-
Patent number: 11858986Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.Type: GrantFiled: November 9, 2020Date of Patent: January 2, 2024Assignees: Pfizer Inc., The Brigham And Women's Hospital, Inc.Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
-
Patent number: 11851466Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.Type: GrantFiled: October 2, 2020Date of Patent: December 26, 2023Assignee: Xencor, Inc.Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
-
Patent number: 11851489Abstract: The present invention provides a protein complex comprising heterodimerizing regions HRI and HRII, each comprised of antiparallel ?-strands and intervening regions wherein HRI and HRII are each interspersed fusion proteins of two human constant regions of an immunoglobulin or immunoglobulin-like proteins. The present invention also provides nucleic acid molecules comprising a sequence encoding said protein complexes and vectors comprising the nucleic acid. The present invention also provides the protein complex, the nucleic acid and the vector for use as a medicament. The present invention further provides a method of determining the amino acid sequence of HRI and/or of the amino acid sequence of HRII. The present invention also provides a method of producing amino acid chains of HRI and/or amino acid chains of HRII. The present invention further provides the protein complex for use in the N prophylaxis, treatment or diagnosis of a disorder or a disease.Type: GrantFiled: June 1, 2018Date of Patent: December 26, 2023Assignee: UNIVERSITÄT STUTTGARTInventors: Fabian Richter, Oliver Seifert, Roland Kontermann
-
Patent number: 11845796Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.Type: GrantFiled: September 20, 2018Date of Patent: December 19, 2023Assignee: WUXI BIOLOGICS IRELAND LIMITEDInventors: Jianqing Xu, Zhuozhi Wang, Jing Li
-
Patent number: 11834693Abstract: The present invention relates to a method for producing a fusion polynucleotide encoding a polypeptide of interest. The method comprises the steps of providing a first polynucleotide and a second polynucleotide, and contacting said first polynucleotide and second polynucleotide with a type IIs restriction endonuclease and a ligase under conditions that allow for the cleavage of the first polynucleotide and second polynucleotide by said type IIs restriction endonuclease and the ligation of the resulting cleavage products, thereby producing the fusion polynucleotide encoding the polypeptide of interest. The first polynucleotide comprises the 5? portion of an intron, and the second polynucleotide comprises the 3? portion of an intron. Further envisaged by the present invention is a polynucleotide encoding a polypeptide of interest, which, when transcribed in a eukaryotic host cell, is transcribed into a transcript comprising at least five introns which are heterologous to said polynucleotide.Type: GrantFiled: September 19, 2019Date of Patent: December 5, 2023Assignee: SANOFIInventors: Wulf Leuschner, Werner Dittrich, I, Joerg Birkenfeld, Marion Schneider
-
Patent number: 11834654Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.Type: GrantFiled: November 10, 2020Date of Patent: December 5, 2023Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 11834503Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.Type: GrantFiled: June 7, 2022Date of Patent: December 5, 2023Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
-
Patent number: 11834494Abstract: The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.Type: GrantFiled: July 26, 2017Date of Patent: December 5, 2023Assignee: Washington UniversityInventors: Michael S. Diamond, Daved Fremont, Haiyan Zhao, Estefania Fernandez, Derek Platt, Christopher Nelson
-
Patent number: 11827692Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.Type: GrantFiled: March 8, 2023Date of Patent: November 28, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Patent number: 11820832Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.Type: GrantFiled: January 27, 2017Date of Patent: November 21, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
-
Patent number: 11820801Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.Type: GrantFiled: April 26, 2019Date of Patent: November 21, 2023Assignee: Good T Cells, Inc.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11814441Abstract: The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.Type: GrantFiled: January 22, 2019Date of Patent: November 14, 2023Assignee: X-BODY, INC.Inventors: Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
-
Patent number: 11807686Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: GrantFiled: May 30, 2018Date of Patent: November 7, 2023Assignee: Bristol-Myers Squibb CompanyInventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
-
Patent number: 11789029Abstract: A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.Type: GrantFiled: June 19, 2020Date of Patent: October 17, 2023Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Briana Martinez, Sarah Stabenfeldt, Chris Diehnelt, Nicholas Stephanopoulos, Crystal Willingham, Amanda Witten, Kendall Lundgreen
-
Patent number: 11780915Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.Type: GrantFiled: September 11, 2018Date of Patent: October 10, 2023Assignee: MONASH UNIVERSITYInventors: Justin Hamilton, Mark Sleeman
-
Patent number: 11780907Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.Type: GrantFiled: January 24, 2019Date of Patent: October 10, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
-
Patent number: 11773162Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.Type: GrantFiled: August 4, 2017Date of Patent: October 3, 2023Assignee: Allakos, Inc.Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
-
Patent number: 11773165Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.Type: GrantFiled: May 4, 2022Date of Patent: October 3, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ravindra Majeti, Irving L. Weissman
-
Patent number: 11760790Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: February 21, 2019Date of Patent: September 19, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
-
Patent number: 11760791Abstract: Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma.Type: GrantFiled: September 13, 2018Date of Patent: September 19, 2023Assignee: RADIMMUNE THERAPEUTICS, INC.Inventors: Ekaterina Dadachova, David J. Rickles
-
Patent number: 11753655Abstract: The present disclosure provides methods and compositions for the treatment of diseases and/or disorders in a subject, including, but not limited to neurological disorders such as giant axonal neuropathy. The methods described herein include direct administration of a gene therapy (e.g. an rAAV viral vector) to a subject via injection into a vagus nerve (e.g. the left vagus nerve) of the subject.Type: GrantFiled: April 14, 2021Date of Patent: September 12, 2023Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Rachel M. Bailey, Steven J. Gray
-
Patent number: 11753469Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: August 10, 2020Date of Patent: September 12, 2023Assignee: Anji Bruno, LLCInventors: Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
-
Patent number: 11753668Abstract: The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of sing thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: GrantFiled: February 2, 2022Date of Patent: September 12, 2023Assignee: Biogen MA Inc.Inventors: Fernie Mitchelson, Erik Hughes, Jessica Mondia, Robin Parish Hyde-Deruyscher
-
Patent number: 11739149Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.Type: GrantFiled: December 5, 2019Date of Patent: August 29, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
-
Patent number: 11732048Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.Type: GrantFiled: November 2, 2021Date of Patent: August 22, 2023Assignees: Bergen Teknologioverføring AS, BerGenBio ASAInventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
-
Patent number: 11732052Abstract: Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.Type: GrantFiled: April 2, 2020Date of Patent: August 22, 2023Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Patent number: 11732040Abstract: This invention relates to the dual targeting of cell inhibiting agents to the cell surface receptors CD7 and CD33 in the treatment of hematological malignancy. In particular, the invention relates to cell inhibiting agents that bispecifically binds to CD33 and CD7 for use in the treatment of a CD7+CD33+ hematological malignancy. Such agents may comprise bispecific antibody drug conjugates.Type: GrantFiled: November 27, 2018Date of Patent: August 22, 2023Assignee: BIVICTRIX LIMITEDInventor: Tiffany Jane Daniels
-
Patent number: 11732045Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: October 1, 2020Date of Patent: August 22, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Pankaj Gupta, Priyanka Gupta, Marcio Lasaro, Justin M. Scheer, Vladimir H. Voynov
-
Patent number: 11725024Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.Type: GrantFiled: April 27, 2022Date of Patent: August 15, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: He Xu, Hong Myung Lee, Christopher Arendt
-
Patent number: 11702470Abstract: Provided herein are methods for promoting axonal regeneration of sensory neurons and functional recovery of neurons following peripheral nerve injury in a subject experiencing aging-dependent nerve regenerative decline, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to CXCL13.Type: GrantFiled: June 8, 2021Date of Patent: July 18, 2023Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Simone Di Giovanni, Luming Zhou
-
Patent number: 11692040Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: May 17, 2021Date of Patent: July 4, 2023Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 11679082Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.Type: GrantFiled: November 23, 2021Date of Patent: June 20, 2023Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
-
Patent number: 11667717Abstract: Disclosed are antibodies binding to human IL-4R, having identical variable regions and different constant regions, wherein the variable regions can specifically bind to human IL-4R, and the constant regions affect the activity of the whole antibody through an amino acid site mutation. The above-mentioned antibodies can be used to treat diseases related to IL-4R overexpression, such as atopic dermatitis, asthma, etc., and thus possesses good clinical application prospects.Type: GrantFiled: August 20, 2019Date of Patent: June 6, 2023Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.Inventors: Jie Zhao, Liangfeng Jiang, Chen Chen, Huiling Wu, Yuping Huang, Haomin Huang, Zhenping Zhu